4DX Share Price Performance

AU$4.25

4.01 (1,670.83%)

AU$4.97

Fair Value

AU$4.25

4.01 (1,670.83%)

14.4% undervalued

AU$4.97

Fair Value

AU$4.25

AU$4.97

AU$11.11

Thu, 18 Jun 26

Fair ValueAU$4.97

Share Pricen/a

4DX Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value AU$4.97 14.4% undervalued

Recent Regulatory Wins And Reimbursement Approvals Will Drive Broader Market Access

ethanwong's

Fair Value

Fair Value AU$11.11 61.7% undervalued

4DMedical will begin to soar with rapid expansion and growth over the next year, (And scale majorly over the next 3 years)

About 4DX

Founded: 2012
Employees: 124
CEO: Andreas Fouras
WebsiteView website: 4dmedical.com

4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in the medical research technology and development of a non-invasive respiratory imaging solution using four-dimensional imaging. It offers CT:VQ, non contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner. The company was incorporated in 2012 and is based in Carlton, Australia.

Recent 4DX News & Updates

Announcement • Jun 29

4Dmedical Receives Tga Approval for Ct:Vq Technology

4DMedical Limited announced that CT:VQ technology has Therapeutic Goods Administration (TGA) approval and is included on the Australian Register of Therapeutic Goods (ARTG)—enabling commercial deployment across Australia. CT:VQ gives physicians access to ventilation and perfusion imaging and data derived directly from routine, non-contrast, chest CT scans. CT:VQ delivers regional functional lung information without the use of injected contrast agents, radiotracers, or dedicated nuclear medicine infrastructure. Ventilation-perfusion imaging typically requires dedicated nuclear medicine equipment, radiotracers, and specialized operational workflows. CT:VQ provides a software-based alternative that integrates off scans performed from existing CT imaging infrastructure—potentially expanding access to functional lung assessment across a broader range of healthcare settings. CT:VQ approval comes as healthcare systems increasingly seek scalable and affordable technologies that expand diagnostic capabilities by leveraging existing imaging resources. Using standard CT infrastructure already available across Australia, CT:VQ can broaden access to functional lung imaging in metropolitan, regional, and rural settings. CT:VQ can be particularly valuable for both facilities that lack onsite nuclear medicine services, and for hospitals and imaging centres that do, by helping preserve nuclear medicine capacity for their other diagnostic and therapeutic services. Since receiving FDA clearance in 2025, CT:VQ has been deployed at leading U.S. institutions including Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, University of Miami, and SimonMed, one of the largest private outpatient radiology networks in the United States. CT:VQ is a non-contrast ventilation-perfusion imaging solution that derives regional lung function information from routine chest CT scans. Unlike conventional nuclear medicine ventilation-perfusion imaging, CT:VQ does not require radiotracers, injected contrast agents, specialized cameras, or dedicated nuclear medicine infrastructure. It uses scans produced from existing CT imaging resources to generate functional lung information. CT:VQ is a non-contrast imaging solution that does not require injected contrast agents, inhaled radiotracers, or radioactive isotopes. TGA approval allows CT:VQ to be commercially deployed across Australia and supports wider access to functional lung imaging using existing CT infrastructure already available in healthcare facilities nationwide. CT:VQ holds regulatory clearance in Australia, the United States, European Union, United Kingdom, Canada, and New Zealand. It has been deployed at leading U.S. health systems including Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, University of Miami, and SimonMed, one of the largest private outpatient radiology networks in the United States.

Recent updates

No updates

4DMedical Limited Stock Price

4DX Share Price Performance

4DX Community Narratives

Recent Regulatory Wins And Reimbursement Approvals Will Drive Broader Market Access

4DMedical will begin to soar with rapid expansion and growth over the next year, (And scale majorly over the next 3 years)

4DMedical will begin to soar with rapid expansion and growth over the next year, (And scale majorly over the next 3 years)

Recent Regulatory Wins And Reimbursement Approvals Will Drive Broader Market Access

Trending Discussion

Recently Updated Narratives

4DMedical will begin to soar with rapid expansion and growth over the next year, (And scale majorly over the next 3 years)

4DX: European AI Lung Imaging Expansion Will Support Higher Future Earnings Multiple

Snowflake Analysis

4DMedical Limited Key Details

About 4DX

Recent 4DX News & Updates

4DMedical Wins TGA Approval to Commercialize CT:VQ Lung Imaging Across Australia

4Dmedical Receives Tga Approval for Ct:Vq Technology

4DMedical (ASX:4DX) Shares Could Be 59.1% Undervalued After Philips Webinar Interest

Recent updates

4DMedical Limited Competitors

Sonic Healthcare

Ramsay Health Care

Cochlear

Ansell